558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study
Notice bibliographique
Résumé
<h3>Background</h3> Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal tumors. Patients with ccRCC who fail checkpoint inhibitors (CPIs) and tyrosine kinase inhibitors (TKIs) have a poor prognosis. Preclinical studies identified substantial expression of CD70 in ccRCC tumor samples. Here, we report results from the Phase 1 dose-escalation study of CTX130™, a CD70-targeting allogeneic CAR T cell therapy in patients with ccRCC. <h3>Methods</h3> COBALT-RCC (NCT04438083) is a Phase 1, open-label, multicenter, global study evaluating safety and efficacy of CTX130 in patients ≥18y with advanced (unresectable or metastatic), relapsed, or refractory (R/R) ccRCC and prior exposure to both CPIs and TKIs. Patients received standard lymphodepleting chemotherapy with fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 for 3 days, followed by CTX130 infusion. <h3>Results</h3> As of May 2, 2022, 14 patients with a median age of 64.5y (range, 54-77) were treated with CTX130. All patients had stage IV disease, and received a median of 3 (range, 1-6) prior treatments. Six patients had documented refractory disease at study entry. Median CD70 expression level on the tumors was 100% (range, 1-100%). Patients received CTX130 at dose levels (DLs) ranging from 3x10<sup>7</sup> to 9x10<sup>8</sup> CAR T cells. Overall, expansion occurred across all DLs. An emerging relationship between higher CAR T exposure and disease control was observed. CTX130 had an acceptable safety profile; there were no dose-limiting toxicities across all DLs. Seven (50%) patients experienced grade (Gr) 1-2 cytokine release syndrome (CRS); there was no Gr≥3 CRS. Three patients experienced serious adverse events (SAEs) related to CTX130; all were episodes of CRS. Three patients had SAEs of infections, all unrelated to CTX130, including a Gr5 pneumonia with Gr4 dyspnea resulting in death. No patients experienced immune effector cell associated neurotoxicity syndrome, graft versus host disease, or hemophagocytic lymphohistiocytosis. One patient (7.7%) had a durable complete remission (CR) maintained at 18+ months and 9 (69.2%) patients had stable disease (SD) with 4 patients (30.8%) in SD at 4 months. The disease control rate (CR + partial response + SD) was 76.9%. <h3>Conclusions</h3> This first-in-human clinical trial exploring CD70 CAR T-cell therapy in ccRCC showed an excellent safety profile with no unexpected on-target off-tumor toxicities and encouraging antitumor activity. To our knowledge, this durable CR is the first to be achieved with allogeneic CAR T cell therapy in patients with R/R solid tumors and represents a proof-of-concept for further exploration of CD70-targeted CAR T cells in ccRCC and other CD70+ malignancies. <h3>Trial Registration</h3> This study is registered at www.ClinicalTrials.gov. NCT04438083 <h3>Ethics Approval</h3> The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH Guidelines for GCP and applicable regulatory requirements. This study was approved by all participating Institutional Review Boards (IRBs). The Ethics Committee/IRB Approval Numbers/IDs for each participating institution are as follows: City of Hope (189473), Huntsman Cancer Institute (00133621), MD Anderson Cancer Center (2020-0151), Yale Cancer Center (20202730), Princess Margaret Cancer Centre (20-5071), Netherlands Cancer Institute (METC20.1170/M20CTX), and Peter MacCallum Cancer Centre (20/16). All participants provided informed consent before taking part in the study.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».